ADC Therapeutics S.A. (ADCT) — Financial statements
Income statement, balance sheet, and cash flow for ADC Therapeutics S.A. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 81↑14.9% | 71↑1.8% | 70↓66.9% | 210↑518.9% | 34 | |
| Cost of Revenue | 8↑29.0% | 6↑135.2% | 3↓23.4% | 3↑137.0% | 1 | |
| Gross Profit | 74↑13.6% | 65↓3.2% | 67↓67.6% | 207↑535.2% | 33 | |
| Operating Expenses | ||||||
| R&D Expenses | 104↓5.1% | 110↓13.8% | 127↓31.8% | 186↑18.0% | 158 | |
| General & Administrative Expenses | 37↓43.3% | 64↓11.5% | 73↓32.4% | 108↑50.8% | 71 | |
| Selling & Marketing Expenses | -43↓302.3% | 21↓35.0% | 33↓7.7% | 36↓44.8% | 65 | |
| SG&A Expenses | -7↓107.9% | 86↓18.9% | 106↓26.2% | 143↑5.3% | 136 | |
| Other Expenses | 85 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 182↓6.9% | 196↓16.1% | 233↓29.4% | 330↑12.1% | 294 | |
| Total Costs & Expenses | 190↓5.8% | 201↓14.5% | 236↓29.3% | 333↑12.7% | 296 | |
| Operating Results | ||||||
| Operating Income | -108↑17.0% | -131↑21.3% | -166↓34.6% | -123↑52.9% | -262 | |
| Depreciation & Amortization | 2↓42.7% | 3↑0.3% | 3↑36.8% | 2↓9.2% | 3 | |
| EBITDA | -107↓3.8% | -103↑29.6% | -146↓35.4% | -108↑53.3% | -231 | |
| EBIT | -108↓2.3% | -106↑29.0% | -149↓35.4% | -110↑52.8% | -233 | |
| Interest & Other Income | ||||||
| Net Interest Income | -43↓12.9% | -38↓6.0% | -36↓4.7% | -34↓86.9% | -18 | |
| Interest Income | 9↓28.2% | 12↑16.4% | 11↑310.4% | 3↑3790.9% | 0.07 | |
| Interest Expense | 52↑2.8% | 50↑8.4% | 46↑26.1% | 37↑100.3% | 18 | |
| Non-Operating Income | 0.00↑100.0% | -25↓46.4% | -17↓27.4% | -13↑53.6% | -29 | |
| Other Income / Expenses | -34↓27.3% | -27↑22.7% | -35↓4.2% | -34↓428.5% | 10 | |
| Income Before Tax | -143↑9.4% | -158↑21.5% | -201↓28.1% | -157↑37.6% | -252 | |
| Income Tax Expense | -0.16↓194.6% | 0.17↓99.6% | 39↑17127.3% | 0.23↑101.1% | -21 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -143↑9.6% | -158↑34.2% | -240↓52.8% | -157↑31.7% | -230 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -143↑9.6% | -158↑34.2% | -240↓52.8% | -157↑31.7% | -230 | |
| Bottom-Line Net Income | -143↑9.6% | -158↑34.2% | -240↓52.8% | -157↑31.7% | -230 | |
| EPS (Basic) | -1.12↑30.9% | -1.62↑44.9% | -2.94↓47.7% | -1.99↑33.7% | -3.00 | |
| EPS (Diluted) | -1.12↑30.9% | -1.62↑44.9% | -2.94↓47.7% | -1.99↑33.7% | -3.00 | |
| Weighted Average Shares | 127↑30.8% | 97↑18.9% | 82↑4.6% | 78↑1.8% | 77 | |
| Weighted Average Diluted Shares | 127↑30.8% | 97↑18.9% | 82↑4.6% | 78↑1.8% | 77 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.